Canadian pharmaceutical purchase Bausch Lomb & for $ 8.7 bihões

The Canadian Valeant pharmaceutical group announced on Monday (27) an agreement for the purchase of the American maker of ophthalmic products Bausch Lomb & for $ 8.7 billion.
Thanks to this agreement, Valeant will pay about $ 4.5 billion to the main shareholder of Bausch Lomb &, the investment fund Warburg Pincus, and $ 4.2 billion to shoot down the debts of the group, said in a statement.
The Bausch Lomb & is specialized in the manufacturing of contact lenses and products used in its maintenance.